2017 San Antonio Breast Cancer Symposium (SABCS)

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

2017 San Antonio Breast Cancer Symposium (SABCS)

05 December 2017 - 09 December 2017

Statins linked to better breast cancer-specific survival

Jackey Suen, 20180103041543

Women with breast cancer who took statins regularly had significantly better breast cancer-specific survival than those who did not take any statins, a Swedish study has shown. [SABCS 2017, poster P2-13-03]

Acupuncture effectively reduces joint pain among breast cancer patients on aromatase inhibitors

Dr. Joseph Delano Fule Robles, 20171215092659

A recent study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) showed that acupuncture is effective in reducing aromatase inhibitor–induced joint symptoms among breast cancer patients.

Adding trastuzumab to adjuvant chemo does not improve outcomes in HER2-low breast cancer

Christina Lau, 20171215041209

Adding trastuzumab to standard adjuvant chemotherapy does not improve survival or reduce recurrence in patients with early-stage breast cancer expressing low levels of HER2, according to results of a National Surgical Adjuvant Breast and Bowel Project study reported at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Pembrolizumab overcomes trastuzumab resistance in advanced breast cancer

Dr. Joseph Delano Fule Robles, 20171213073227

The phase IB/II PANACEA study recently showed that the addition of pembrolizumab to trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer resulted in disease control with a tolerable safety profile.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!

FLAG-GO vs FLAG-Ida regimen leads to better relapse-free survival in CBF acute myeloid leukaemia

Stephen Padilla, 16 Dec 2019

Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.

Switching to ixazomib-based induction feasible, effective in newly diagnosed multiple myeloma

Stephen Padilla, 12 Dec 2019

Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Daratumumab add-on to RVd boosts response rates in transplant-eligible NDMM

Elaine Soliven, 17 Dec 2019

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.